RxDoctor Payments Data

Gloria Hui, MD

Cardiovascular Disease · Houston, TXNPI 1821030438

Payments from drug & device makers

$45,787in general payments, 2019–2025

Across 858 payments — averaging $53.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron$11K
  • Novo Nordisk$6K
  • AstraZeneca$5K
  • Johnson & Johnson$3K
  • Medtronic$3K
  • Novartis$3K
  • plus $15K from 46 others

What the payments were for

  • Consulting fees$16,09835%
  • Speaking & faculty fees$170%
  • Travel & lodging$2,4835%
  • Food & beverage$27,05459%
  • Education$1350%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$45,787 in reported general payments places this provider in the 85th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$201,034
Medicare patients
639
Services billed
3,000

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban276$330,400
UptraviSelexipag11$267,214
XareltoRivaroxaban231$241,439
FarxigaDapagliflozin Propanediol149$160,970
OpsumitMacitentan13$149,530
OzempicSemaglutide93$146,992
EntrestoSacubitril/Valsartan84$94,291
JardianceEmpagliflozin36$44,720
Repatha SureclickEvolocumab24$35,090
VascepaIcosapent Ethyl38$33,741
MultaqDronedarone Hcl21$26,694
Xigduo XrDapaglifloz Propaned/Metformin14$14,762
TrulicityDulaglutide11$11,930
EdarbiAzilsartan Medoxomil17$9,290
Rosuvastatin Calcium509$8,046

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit$1,010$416,74524 claims
PfizerEliquis$338$330,400276 claims
Johnson & JohnsonXarelto$2,967$241,439231 claims
AstraZenecaFarxiga$4,966$160,970149 claims
Novo NordiskOzempic$6,324$146,99293 claims
NovartisEntresto$2,719$94,29184 claims
Boehringer IngelheimJardiance$632$44,72036 claims
Sanofi-aventis U.S. LLCMultaq$415$26,69421 claims
Lilly USA, LLCTrulicity$352$11,93011 claims
Arbor Pharmaceuticals, Inc.Edarbi$262$9,29017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →